Xin Yu, Xi Fang^*

CMC-Computers, Materials & Continua, Vol.87, No.3, 2026, DOI:10.32604/cmc.2026.075607 - 09 April 2026

Abstract This paper addresses the challenging problem of multi-agent dynamic target pursuit under stringent communication constraints (including delays and range limits), where the agile targets are non-cooperative and free from such limitations. To tackle this, we propose CRS-DQN, a novel Deep Q-Network algorithm designed for this scenario. CRS-DQN enables agents to learn effective pursuit strategies through deep reinforcement learning despite partial observability and constrained information sharing. Simulation experiments systematically evaluate the impact of key parameters. The results show that pursuit performance degrades monotonically with increased communication delay. In contrast, the communication radius exhibits a non-linear effect: More >

Maureen Veilleux^1,2,#, Anh Nguyen^3,#, Charles Cao^4,#, Yihui Shi^2,*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.072194 - 23 March 2026

Abstract ADP-ribosyltransferases (ARTs) regulate key processes in cancer, including DNA repair, transcription, immune responses, and treatment resistance. The clostridial toxin-like ADP-ribosyltransferase (ARTC) family and the diphtheria toxin-like ADP-ribosyltransferase (ARTD) family play a crucial role in genomic stability by modification of proteins either with mono(ADP-ribosyl)ation (MARylation) or poly(ADP-ribosyl)ation (PARylation). These ARTs are promising therapeutic targets and could serve as biomarkers in cancer management. This review explores the roles of these enzymes and current knowledge on specific inhibitors. A literature search was conducted in PubMed and Google Scholar to identify studies published between 1992 and 2025 on ADP-ribosyltransferases… More >

Yimao Wu^1,2,#, Yitong Liu^2,#, Ruowei Sun^3,#, Yiyuan Zhang², Qian Zhang^4,*, Chen Li^5,*, Mengyao Li^1,6,*

Oncology Research, Vol.34, No.3, 2026, DOI:10.32604/or.2026.075012 - 24 February 2026

Abstract Tumor metabolic reprogramming is a core hallmark of cancer, characterized by pathways such as aerobic glycolysis, aberrant lipid metabolism, and glutaminolysis that support rapid proliferation and immunosuppressive microenvironments. Circular RNAs (circRNAs) are highly stable, evolutionarily conserved non-coding RNAs that have emerged as critical modulators of these metabolic shifts. This review aims to systematically elucidate the roles and mechanisms of circRNAs in reprogramming tumor metabolism, and to discuss their clinical potential as biomarkers and therapeutic targets. Through mechanisms including miRNA sponging, protein interactions, regulation of mitochondrial dynamics, and modulation of metabolic enzymes, circRNAs influence key metabolic… More >

Gizem Kaynar Beyaz^1,*, Ahmet Kirbas², Sevgi Kalkanli Tas¹

BIOCELL, Vol.50, No.1, 2026, DOI:10.32604/biocell.2025.072368 - 23 January 2026

Abstract Peripheral artery disease (PAD) remains a significant global health issue, with current treatments primarily focused on relieving symptoms and addressing macrovascular issues. However, critical immunoinflammatory mechanisms are often overlooked. Recent evidence suggests that monocyte phenotypic plasticity plays a central role in PAD development, affecting atherogenesis, plaque progression, ischemia-reperfusion injury, and chronic ischemic remodeling. This narrative review aims to summarize the latest advances (2023–2025) in understanding monocyte diversity, functional states, and their changes throughout different stages of PAD. We discuss both established and emerging biomarkers, such as circulating monocyte subset proportions, functional assays, immune checkpoint expression, More >

Harpreet Kaur^1,*, Dhrubalochan Rana², Sowvik Bag², Paramjeet Singh³

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.071209 - 19 January 2026

Abstract The prolonged and intricate history of oncological treatments has transitioned significantly since the introduction of chemotherapy. Substantial therapeutic benefits in cancer therapy have been achieved by the integration of conventional treatments with molecular biosciences and omics technologies. Human epidermal growth factor receptor, hormone receptors, and angiogenesis factors are among the established therapies in tumor reduction and managing side effects. Novel targeted therapies like KRAS G12C, Claudin-18 isoform 2 (CLDN18.2), Trophoblast cell-surface antigen 2 (TROP2), and epigenetic regulators emphasize their promise in advancing precision medicine. However, in many cases, the resistance mechanisms associated with these interventions… More > Graphic Abstract

Fu Zhang^1,2, Miao Lin^1,2, Yuancong Jiang³, Fangjian Zhou^1,2,*

European Cytokine Network, Vol.36, No.1, pp. 1-5, 2025, DOI:10.1684/ecn.2025.0500

Abstract Interleukin-33 (IL-33), a key member of the IL-1 family, plays a significant role in inflammation and cancer. Its classic receptors, ST2 and IL-1 receptor accessory protein (IL-1RAcP), are predominantly expressed in immune cells such as T helper 2 (Th2) cells and mast cells. Recent studies have highlighted the involvement of IL-33 in breast cancer, demonstrating its ability to exert dual functional effects by modulating both innate and adaptive immune responses within the tumour microenvironment. However, the precise molecular mechanisms linking IL-33 to breast cancer pathogenesis and its potential as a target for molecularly targeted therapies More >

Amber Hassan¹, Badr Hafiz², Taghreed Alsinani³, Rakan Bokhari⁴, Dahlia Mirdad⁵, Awab Tayyib⁵, Alaa Alkhotani⁶, Ahmad Fallata⁷, Iman Mirza⁸, Eyad Faizo^9,10, Saleh Baeesa², Huda Alghefari¹¹, Maher Kurdi^11,*

Oncology Research, Vol.33, No.11, pp. 3293-3325, 2025, DOI:10.32604/or.2025.070031 - 22 October 2025

Abstract Background: Glioblastoma (GBM) remains the most aggressive primary brain tumour in adults, marked by pronounced cellular heterogeneity, diffuse infiltration, and resistance to conventional treatment. In recent years, transcriptomic profiling has provided valuable insights into the molecular mechanisms that govern the progression of glioblastoma. This systematic review aims to synthesise the current literature on dysregulated gene expression in GBM, focusing on gene signatures associated with stemness, immune modulation, extracellular matrix remodelling, metabolic adaptation, and therapeutic resistance. Methods: We conducted a systematic search of PubMed, The Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA), and the GlioVis… More >

Bruno Špiljak^1,#, Bojan Poposki^2,#, Stjepanka Lešić^3,*

Oncology Research, Vol.33, No.11, pp. 3269-3292, 2025, DOI:10.32604/or.2025.068395 - 22 October 2025

Abstract Head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer with high recurrence rates and prevalent resistance to therapeutic interventions. Tumor behavior is largely dependent on the tumor microenvironment (TME) that includes immune cells, stromal components, cancer-associated fibroblasts (CAFs), the extracellular matrix (ECM), and an associated cytokine network. In this review, we examine principal mechanisms of the tumorigenic transformation, encompassing immune checkpoint disruption, therapy resistance mediated through CAFs, the contribution of hypoxic niches, and several metabolic dependencies that hold potential as future targets. Novel therapeutics developed and/or repurposed, such as immune checkpoint inhibitors (ICIs),… More >

FANG CHEN¹, DONGQIANG YANG², YUHUA RU³, SHAN CAO¹, AISHE GAO¹

Oncology Research, Vol.33, No.7, pp. 1799-1800, 2025, DOI:10.32604/or.2025.064363 - 26 June 2025

Abstract This article has no abstract. More >

YU HONG^1,#, YUNXIANG TANG^1,#, WENYAN ZHOU¹, HANYUE LUO², LINLIN BU², HUI QIU^3,*, QIUJI WU^3,*

Oncology Research, Vol.33, No.6, pp. 1347-1361, 2025, DOI:10.32604/or.2025.059327 - 29 May 2025

Abstract As a rising immune checkpoint on tumor cells, CD24 is closely related to tumorigenesis and progression. CD24 can directly regulate the malignant behavior of tumor cells and indirectly inhibit the function of immune cells in the meantime, which promotes the immune escape of tumor cells, induces cancer invasion and causes poor prognosis. The basic principle of cancer treatment is to induce cell death and inhibit cell survival. Resistance to chemoradiotherapy is a critical challenge in oncology, which limits the effectiveness of anti-cancer treatments. Many studies have shown a strong association between CD24 and chemoradiotherapy More >